XML 42 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and Intangible Assets, net (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill

The changes in the carrying value of goodwill by segment are as follows (in thousands):

 

 

Proteomics

 

 

Genomics

 

 

Total

 

Balance as of December 31, 2022

 

$

85,752

 

 

$

20,499

 

 

$

106,251

 

Foreign currency translation

 

 

46

 

 

 

20

 

 

 

66

 

Balance as of December 31, 2023

 

$

85,798

 

 

$

20,519

 

 

$

106,317

 

 
Schedule of Finite-Lived Intangible Assets

Intangible assets with finite lives include developed technology, patents and licenses. In the consolidated balance sheets, developed technology is reported separately while patents and licenses are reported in other non-current assets. Intangible assets, net, were as follows (in thousands):

 

 

 

December 31, 2023

 

 

Gross Amount

 

 

Accumulated
Amortization
and
Impairment

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,354

 

 

$

(115,954

)

 

$

1,400

 

 

10.0 years

Patents and licenses

 

$

11,250

 

 

$

(11,243

)

 

$

7

 

 

7.0 years

 

 

 

December 31, 2022

 

 

Gross Amount

 

 

Accumulated
Amortization

 

 

Net

 

 

Weighted-
Average
Amortization
Period

Developed technology

 

$

117,194

 

 

$

(104,594

)

 

$

12,600

 

 

10.0 years

Patents and licenses

 

$

11,247

 

 

$

(10,669

)

 

$

578

 

 

7.0 years

 
Schedule of Estimated Future Intangible Asset Amortization Expense

Based on the net carrying value of intangible assets at December 31, 2023, the Company expects annual amortization expense to be as follows (in thousands):

 

Fiscal Year

 

Developed
Technology
Amortization
Expense

 

 

Patents and
Licenses
Amortization
Expense

 

 

Total

 

2024

 

 

1,400

 

 

 

7

 

 

 

1,407

 

Total

 

$

1,400

 

 

$

7

 

 

$

1,407